ChromaDex Shares Outstanding 2008-2021 | CDXC

ChromaDex shares outstanding from 2008 to 2021. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
ChromaDex Annual Shares Outstanding
(Millions of Shares)
2020 61
2019 57
2018 55
2017 45
2016 37
2015 36
2014 35
2013 33
2012 30
2011 23
2010 16
2009 10
2008 9
2007 9
ChromaDex Quarterly Shares Outstanding
(Millions of Shares)
2021-06-30 68
2021-03-31 64
2020-12-31 61
2020-09-30 62
2020-06-30 61
2020-03-31 60
2019-12-31 57
2019-09-30 58
2019-06-30 56
2019-03-31 55
2018-12-31 55
2018-09-30 55
2018-06-30 55
2018-03-31 55
2017-12-31 45
2017-09-30 48
2017-06-30 42
2017-03-31 38
2016-12-31 37
2016-09-30 38
2016-06-30 37
2016-03-31 37
2015-12-31 36
2015-09-30 36
2015-06-30 36
2015-03-31 36
2014-12-31 35
2014-09-30 36
2014-06-30 35
2014-03-31 35
2013-12-31 33
2013-09-30 34
2013-06-30 33
2013-03-31 32
2012-12-31 30
2012-09-30 31
2012-06-30 30
2012-03-31 28
2011-12-31 23
2011-09-30 24
2011-06-30 22
2011-03-31 21
2010-12-31 16
2010-09-30 20
2010-06-30 15
2010-03-31 10
2009-12-31 10
2009-09-30 10
2009-06-30 10
2009-03-31 10
2008-12-31 9
2008-09-30 10
2008-06-30 10
2008-03-31 9
2007-09-30 7
2007-06-30 7
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.456B $0.059B
ChromaDex Corporation and its subsidiaries supply phytochemical reference standards and reference materials, related contract services, and products for the dietary supplement, nutraceutical, food and beverage, functional food, pharmaceutical and cosmetic markets. ChromaDex's core business strategy is to use the intellectual property harnessed by its expertise in the area of natural products and in the creation of reference materials to the industry as the basis for providing new and alternative, `green`, mass marketable products to its customers. The Company's main priority is to create industry-accepted information, and to provide products and services to every layer of the functional food, pharmaceutical, personal care and dietary supplement markets. The company markets and sells its products in the United States and Canada. It offers its products through distributors in Europe, South America, Korea, India, Japan, Australia, New Zealand, China, Indonesia, Malaysia, Singapore, Thailand, and Mexico.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $134.727B 8.97
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.500B 21.17
Biohaven Pharmaceutical Holding (BHVN) United States $8.865B 0.00
Emergent Biosolutions (EBS) United States $2.891B 6.97
Arcus Biosciences (RCUS) United States $2.641B 0.00
Myovant Sciences (MYOV) United Kingdom $2.145B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.998B 0.00
Zymeworks (ZYME) Canada $1.380B 0.00
Ambrx Biopharma (AMAM) United States $0.521B 0.00
SQZ Biotechnologies (SQZ) United States $0.427B 0.00
Enzo Biochem (ENZ) United States $0.175B 51.71